Lane Generational LLC Boosts Position in Bruker Corporation (NASDAQ:BRKR)

Lane Generational LLC boosted its position in Bruker Corporation (NASDAQ:BRKR - Free Report) by 31.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 87,607 shares of the medical research company's stock after buying an additional 21,055 shares during the quarter. Bruker makes up about 4.0% of Lane Generational LLC's portfolio, making the stock its 12th biggest position. Lane Generational LLC owned about 0.06% of Bruker worth $3,657,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pinnacle Bancorp Inc. bought a new position in shares of Bruker during the 1st quarter worth approximately $29,000. Allworth Financial LP lifted its position in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after acquiring an additional 364 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of Bruker by 274.9% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after acquiring an additional 800 shares during the period. Fifth Third Bancorp lifted its position in shares of Bruker by 54.2% during the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock valued at $46,000 after acquiring an additional 390 shares during the period. Finally, UMB Bank n.a. lifted its position in shares of Bruker by 45.8% during the 1st quarter. UMB Bank n.a. now owns 1,325 shares of the medical research company's stock valued at $55,000 after acquiring an additional 416 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on BRKR shares. Stifel Nicolaus cut their target price on Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research report on Thursday, May 8th. Wells Fargo & Company lowered their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Barclays lowered their price target on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. UBS Group lowered their price target on Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Finally, Bank of America lowered their price target on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Bruker currently has an average rating of "Hold" and a consensus target price of $52.89.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien purchased 2,608 shares of the business's stock in a transaction that occurred on Friday, June 6th. The stock was purchased at an average cost of $38.36 per share, with a total value of $100,042.88. Following the completion of the acquisition, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This trade represents a 0.01% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 27.30% of the company's stock.

Bruker Trading Up 3.9%

Shares of BRKR traded up $1.56 during mid-day trading on Friday, reaching $42.01. 2,541,734 shares of the company's stock traded hands, compared to its average volume of 2,312,735. The stock has a market cap of $6.37 billion, a P/E ratio of 80.78, a P/E/G ratio of 2.69 and a beta of 1.18. The stock's 50-day moving average is $39.40 and its two-hundred day moving average is $44.55. Bruker Corporation has a 12 month low of $34.10 and a 12 month high of $72.94. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. The firm had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. Bruker had a return on equity of 19.47% and a net margin of 2.31%. Bruker's quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.53 earnings per share. Research analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.48%. Bruker's payout ratio is 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.